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Abstract
The human pathogen Group A Streptococcus (Streptococcus pyogenes, GAS) is widely recognized as a major cause of
common pharyngitis as well as of severe invasive diseases and non-suppurative sequelae associated with the existence of
GAS antigens eliciting host autoantibodies. It has been proposed that a subset of paediatric disorders characterized by tics
and obsessive-compulsive symptoms would exacerbate in association with relapses of GAS-associated pharyngitis. This
hypothesis is however still controversial. In the attempt to shed light on the contribution of GAS infections to the onset of
neuropsychiatric or behavioral disorders affecting as many as 3% of children and adolescents, we tested the antibody
response of tic patient sera to a representative panel of GAS antigens. In particular, 102 recombinant proteins were spotted
on nitrocellulose-coated glass slides and probed against 61 sera collected from young patients with typical tic
neuropsychiatric symptoms but with no overt GAS infection. Sera from 35 children with neither tic disorder nor overt GAS
infection were also analyzed. The protein recognition patterns of these two sera groups were compared with those
obtained using 239 sera from children with GAS-associated pharyngitis. This comparative analysis identified 25 antigens
recognized by sera of the three patient groups and 21 antigens recognized by tic and pharyngitis sera, but poorly or not
recognized by sera from children without tic. Interestingly, these antigens appeared to be, in quantitative terms, more
immunogenic in tic than in pharyngitis patients. Additionally, a third group of antigens appeared to be preferentially and
specifically recognized by tic sera. These findings provide the first evidence that tic patient sera exhibit immunological
profiles typical of individuals who elicited a broad, specific and strong immune response against GAS. This may be relevant
in the context of one of the hypothesis proposing that GAS antigen-dependent induction of autoantibodies in susceptible
individuals may be involved the occurrence of tic disorders.
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Introduction
Group A Streptococcus (Streptococcus pyogenes, GAS) is a common
human pathogen responsible for a large variety of infections which
most frequently occur at the level of the upper respiratory tract
and skin causing mild diseases such as pharyngitis, impetigo and
cellulitis. Less frequently, GAS infections result into life-threaten-
ing and invasive conditions, such as bacteremia, pneumonia,
necrotizing fasciitis (NF) and streptococcal toxic shock syndrome
(STSS) [1]. Differently from other streptococci, GAS infections
can also lead to non suppurative sequelae, such as acute rheumatic
fever (RF) and post-streptococcal glomerulonephritis, which
appear to be associated with autoimmune reactions due to
‘‘molecular mimicry’’ between host tissues and M protein, the
major GAS surface-associated antigen. In fact, anti-M specific
antibodies have been proven to cross-react with human tissues,
including the heart, skeletal muscle, brain and glomerular
basement membranes [2].
Post-infectious disorders secondary to GAS infections, especially
RF, may present with a wide array of neurological and psychiatric
pictures, characterized by the association of movement disorders
(mainly chorea and tics) and behavioral disorders (mainly
obsessive-compulsive symptoms, anxiety and mood disorders)
[3]. The systematic classification of post-streptococcal neuropsy-
chiatric disorders is still in progress. Two entities are however
universally acknowledged: Sydenham’s chorea (SC) [4], which
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6332constitutes one of the major criteria for the diagnosis of acute RF,
and post-streptococcal acute disseminated encephalomyelitis
(PSADEM) [5]. In the last 15 years, it has been suggested that
the clinical spectrum of these disorders might be broader.
Particularly, in 1998 Swedo et al. proposed the existence of a
paediatric disorder mainly characterized by tics and obsessive-
compulsive symptoms exacerbating in association with relapses of
streptococcal pharyngitis [6]. They indicated this phenotype with
the acronym PANDAS (Paediatric Autoimmune Neuropsychiatric
Disorders Associated with Streptococcal infections). This hypoth-
esis, however, generated significant controversy, one critical issue
being represented by the difficulty in confirming a temporal
relationship between neuropsychiatric symptoms and GAS
infections [7–9].
In the attempt to shed some light on the possible contribution of
GAS infections to the onset of neuropsychiatric or behavioral
disorders, we assessed whether a broad antibody response against
GAS antigens could be revealed in young patients with tic
disorder, a pathological condition consisting of ‘‘sudden, repetitive,
non-rhythmic, involuntary movements (motor tic) or sounds
(phonic tic) that involve discrete groups of muscles’’ [10]. Sera
obtained from these children were tested for their immunological
reactivity versus a representative panel of GAS antigens. The
analysis was carried out using the protein array technology [11],
which allows high throughput analysis of human sera against a
large number of antigens. Protein chips containing 102 GAS
proteins were probed with sera from tic patients and children
without tics. The resulting data were compared with those
obtained with chips probed with GAS-associated pharyngitis
patient sera. By using this experimental approach, we were able to
better define the relationship between tic disorder and immune
response to GAS antigens.
Results
Micro array design and validation
To study the serological response of tic patient versus a
representative panel of GAS antigens a protein array was
generated by printing 102 recombinant proteins, mainly selected
from the GAS SF370 M1 genome (Table S1, Supplementary
Information). The majority of printed GAS proteins were
expressed as C-terminal His-tag fusions while 23 proteins where
expressed as double fusions, with glutathione S-transferase (GST)
at the N-terminal and with a His-tag at the C-terminal. Proteins
obtained after affinity purification from the bacterial soluble
fraction showed purity levels equal or greater than 70%, as
estimated by densitometric scan of PAGE-SDS gels (Fig. 1A). The
protein array validation was obtained by using a defined printing
scheme and control spots (Figure 1B). Printing 4 replicates of each
antigen followed by incubation with mouse anti-sera raised against
the recombinant proteins and/or GST and His fusion tags,
assured that all of them were efficiently and reproducibly
immobilized on nitrocellulose slides (not shown). PBS buffer,
spotted on either side of each protein spot was used to detect
protein carry-over during spotting and fewer than 10% of PBS
spots showed signal intensities higher than the average nitrocel-
lulose background fluorescence intensity (FI) value (see Materials
and Methods). Proteins eluted after affinity purification of total
soluble extracts from an E. coli strain carrying the empty
expression vectors were also printed on the array to determine
the maximum background signal due to contaminants possibly
generated by incubation with the sera under investigation, which
always resulted in a mean fluorescence intensity (MFI) not higher
than 1023 (Standard deviation, SD, 461). Finally, 8 different
amounts of human IgGs were spotted on the array in 4 replicates
(from 6610
23 to 7610
21 ng of immobilized protein per spot) and
used as controls for detection, system reproducibility and data
normalization. MFIs of human IgG spots, obtained after detection
with Cy3-conjugated anti-human antibodies, were best fitted by
sigmoid curves showing a signal dynamic range of about 2 logs
and, within this range, a linearity covering approximately 1 log of
FI values, with a lower detection limit which resulted to be
approximately 7610
23 ng (Figure 1C). To compare data from
different experiments we used a normalization method previously
set up and validated for our system (Reguzzi V., personal
communication), in which the experimental IgG curve of each
slide was adjusted on a reference sigmoid IgG curve, and the
background-subtracted MFI values of each protein were normal-
ized accordingly (Figure 1D and Materials and Methods). The
definition of the MFI of the reference IgG curve also permitted us
to assess that the intra-slide coefficients of variation (CV) was lower
than 5%, while the inter-slide CV, measured by computation of
human IgG MFI values of 50 slides, ranged from 46% to 30% for
FI values lower than 15,000 (value corresponding to the
normalized MFI value of buffer spots plus 2 standard deviations
as described in Materials and Methods) and decreased to
approximately 20% for FI values higher than 15,000. On the
basis of these results, a normalized FI value of 15,000 was
arbitrarily chosen as the lowest signal threshold for scoring a
protein as positively recognized by human sera. In addition, a
second FI cut off of 40,000 was arbitrarily defined to mark highly
reactive proteins and/or identify high titer sera, which in our
experimental system corresponded approximately to the saturation
segment of the human IgG curve (Figure 1D).
Serological profiling of tic, no tic and pharyngitis sera
In the attempt to determine if there is a link between GAS
infection or exposure to GAS antigens and tic disorders, the GAS
protein array was probed with 61 sera from patients with tics. At the
time of the visit patients did not show clinical signs of pharyngitis
and the percentage of GAS carriers in the group (14.7%) did not
differ from that observed in a normal children population falling in
the same age range [12]. A similar analysis was carried out using 35
sera from children without tic disorder and without pharyngitis
symptoms (referred to as ‘‘no tic’’) and 239 sera from GAS-
pharyngitis patients (confirmed by throat swab and isolation of the
infective GAS strain). All groups were formed by 4–14-year-old
children. Sera reactivity was evaluated by detecting total IgG bound
to eachprotein spot usingfluorescently labeled anti-human IgG and
measuring the FI values for each antigen. To define the antigen
recognition pattern of the three sera groups, the normalized FI
values were subjected to unsupervised bi-dimensional hierarchical
clustering using the Pearson algorithm to calculate cluster distances.
The clustered view of the antibody recognition profiles of the GAS
antigens observed for tic, no tic and pharyngitis patients, for a total
of 335 sera, is shown in Figure 2A. This analysis resulted in the
definition of 5 different major clusters at the second level of
hierarchy. Cluster I included 181 sera (30 tic and 151 pharyngitis),
cluster II 47 sera (19 tic, 26 no tic and 2 pharyngitis), cluster IV 87
sera (11 tic, 8 no tic and 68 pharyngitis). Clusters III (1 tic and 1 no
tic) and V (18 pharyngitis) included a minority of the tested sera.
Most of the tic sera distributed without any statistically significant
difference in clusters I, II and IV, while pharyngitis sera were
grouped in clusters I, IV and V (Figure 2B). Remarkably, nearly
80% of the no tic sera segregated in cluster II, indicating that the
large majority of sera belonging to the negative control group had a
significantly different antigen recognition pattern as compared to
the other two sera classes.
Group A Streptococcus and Tics
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and pharyngitis patients
When we analyzed the tic sera reactivity frequencies for each
single antigen, 50% of them (51 antigens) resulted to be recognized
by at least 30% of the tic patient sera (18 sera), while approximately
25% resulted to be reactive against less than 10% of them. Three
groups of immunogenic antigens could be distinguished: (i) one
consisting of 25 proteins (Table 1), which were recognized with
similar frequencies by all three sera families. Several known
immunogenic GAS antigens fell in this subset, such as M proteins,
streptolysin O (SLO), streptokinase A and C5a peptidase precur-
sors. The fact that these antigens were also recognized by sera
belonging to the no tic negative control group, was not considered
contradictory since these individuals had most probably already
experienced GAS infections; (ii) another group of 21 proteins
(Table 2), recognized with comparable frequencies by both tic and
pharyngitis sera butwith statisticallysignificant lower frequencies by
no tic sera; (iii) a third group of 5 proteins (Table 3 and Figure S1,
Supplementary Information), which were instead recognized with
statistically significant higher recognition rates by tic sera compared
to both pharyngitis and no tic sera. Interestingly, approximately
40% of tic sera (24 out of 61 tested) were simultaneously reactive
against at least 3 of these antigens (Table 4).
The possibility that a correlation existed between the observed
serological profiles and an ongoing or recent GAS infection was
evaluated by considering the anti streptolysin O (ASO) titers of tic
patients. According to our previous works [13] we fixed the cut-off
of 407 International Units (I.U.) to define high or low ASO titer.
When 31 tic sera with high ASO were compared to 16 tic sera with
low ASO, we did not observe major differences neither in the type
nor in the total number of recognized GAS antigens (not shown).
To confirm and further validate our data, IgG levels against few
test antigens included in the three groups were analyzed by
standard methods. When 8 negative sera (MFI,15,000) and 8
positive sera (MFI.15,000) against each of the antigens Spy0843,
M5005_Spy0249, Spy 1306 and Spy 1939 were tested by ELISA,
Figure 1. Protein micro array set-up and validation. A, SDS-PAGE analysis of purified recombinant GAS proteins stained with Coomassie.
Molecular weight markers in lane 1. B, Representative image of a chip after incubation with a human serum and with Cy3-labelled anti-human IgG
and Cy5-labelled anti-human IgM. Replicates of tested antigens and of negative and positive IgG and IgM controls are highlighted. C, graphic
representation of the control human IgG curve. Orange dots correspond to the different IgG concentrations measured on the x-axis, while the
continuous line corresponds to the interpolated resulting curve. MFIs values are reported on the y-axis. The chip image of different IgG concentration
revealed by incubation with anti-human IgG-Cy3 is shown below the graph. D, Sigmoid-derived data normalization method. Data are normalized
using the sigmoid control curve (black) referred to a reference sigmoid curve (red). IgG control concentrations and MFIs are reported on the x- and
the y-axis respectively. HL, high level signal area (normalized MFI value .40,000); LL, low level signal area (normalized MFI value ,15,000); id, ideal
sigmoid curve; P and P’, intersection points of not normalized and normalized MFI values on the experimental and reference sigmoid curve; Val and N
(Val): Background-subtracted MFI value and normalized value resulting after normalization, respectively.
doi:10.1371/journal.pone.0006332.g001
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6332Figure 2. Tic, No Tic and Pharyngitis sera analysis. A, Unsupervised hierarchical clustering of human Tic (n=61), No Tic (n=35) and Pharyngitis
(n=239) sera versus the 102 selected GAS antigens. Antigens/sera interactions resulting in signals with high or low FI are visualized in yellow and
blue respectively. Color scale of signal intensity is reported on top-left. Clusters group antigens and/or sera showing similar reactivity profiles. Bars
and roman numbers on the right of the dendrogram identify the sera clusters considered for the analysis. Light green lines next to cluster bars
highlight how the 61 tic sera distribute within the dendrogram. Colored bars at the bottom of the dendrogram highlight the distribution of group 1,
group 2 and group 3 antigens, as defined in Tables I, II and III. B, Distribution of sera in the different clusters. The histogram shows the percent of
positive sera (FI.15,000) for each class in relation to the five defined clusters. The number of positive sera in each cluster calculated on the total
number of sera tested for each group is shown in the table below the histogram.
doi:10.1371/journal.pone.0006332.g002
Group A Streptococcus and Tics
PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6332statistically significant titer differences were observed among
negative and positive sera, as defined on the basis of the MFIs
resulting from the micro-array analysis (Figure 3).
Comparison of the immunoreactivity of tic sera
The relationship between tic and anti-GAS immune response
wasconfirmed and strengthened by comparingthe overallreactivity
of the three sera families against the 102 antigens spotted on the
chip. While the percentages of antigens recognized by .30% of
tested sera (.18 tic, .72 pharyngitis and .10 no tic sera) were not
remarkably different for the tic and pharyngitis groups (51 and 43
antigens respectively), no tic sera recognized overall fewer antigens
(24 antigens) (Figure 4A). Significant divergences between tic sera
and the other two sera families were instead observed when the
differences in spot intensities were considered, as indicative of
differential antigen-specific IgG levels. In fact, we verified which
were the percentages of antigens recognized most intensely by the
three sera families (FI.40,000, arbitrary cut-off) and, conversely,
which the percentages of sera generating on the array a very high
signal (FI.40,000) against at least 30% of the tested antigens (31
antigens). The percentage of GAS antigens recognized by the tested
sera with FI.40,000 was 36% in the case of tic patients (37
antigens), 21% in the case of pharyngitis patients (21 antigens) and
18% (18 antigens) in the no tic group (Figure 4B). Similarly, 33% of
the tic patient sera (20 sera) reacted very intensively (FI.40,000)
withat least 30%of the spotted antigens (31 antigens), as opposite to
12% of the pharyngitis patient sera (29 sera) and only 3% (1 serum)
of the negative control group sera (Figure 4C). In both cases,
statistical analysis carried out using the x2 test and referring to a P
value,0.05 confirmed that the differences observed between the
reactivity of tic sera and the other two sera groups were statistically
significant.
Discussion
In this work we have addressed the issue of whether a consistent
and strong correlation between tic disorders and GAS infection
could be established. To this purpose, we have carried out the first
systematic analysis of the IgG response of tic patients sera versus a
representative panel of GAS antigens and the resulting data were
compared to those obtained with sera from children either without
tic or with pharyngitis.
The protein micro array approach which we exploited turned
up to be appropriate to test a total of almost 350 human sera
against over 100 bacterial antigens, demonstrating that this
technology should be taken into account whenever large sets of
data on in vivo expression of pathogen antigens and on the
subsequent host immune response are required. Protein micro
array confirmed to be a fast, easy and sensitive approach and the
results that we obtained with the different controls were sufficiently
Table 1. GAS antigens reacting against tic, pharyngitis and no tic sera.
SPy
(a) Annotation Tic Phar
(b) No Tic
SPy0269 putative surface exclusion protein 98 89 93
gi-507127 M protein type 9 97 87 89
SPy2010 C5A peptidase precursor 92 67 89
MGAS10270_SPy1784 M protein type 2 89 94 83
SPy1801 immunogenic secreted protein precursor homolog 89 84 83
SPy1813 hypothetical protein 89 82 94
SPy1979 streptokinase A precursor 89 81 94
SPy1361 putative internalin A precursor 89 80 91
gi-126660 M protein type 12 89 66 86
SPy0167 streptolysin O precursor 89 63 97
SPy0843 hypothetical protein 87 81 74
SPy0857 putative peptidoglycan hydrolase 87 76 94
gi-4586375 M protein type 23 87 74 83
SPy2025 immunogenic secreted protein precursor 87 59 89
SPyM3_1727 M protein type 3 85 83 86
SPy0416 putative cell envelope proteinase 85 62 83
SPy2043 mitogenic factor 82 59 91
SPy2018 M protein type 1 74 85 63
SPy0019 putative secreted protein 74 49 83
SPy1972 putative pullulanase 70 50 60
SPy0457 putative cyclophillin-type protein 57 46 34
SPy2009 hypothetical protein 46 33 26
SPy1733 putative transcription regulator 43 35 26
SPy0436 putative exotoxin 38 25 31
SPy1007 streptococcal exotoxin I 30 40 43
Numeric values refer to % of positive sera of each class versus each antigen.
(a)When the SPy number is not available, the gi- number is indicated.
(b)Pharyngitis.
doi:10.1371/journal.pone.0006332.t001
Group A Streptococcus and Tics
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further confirmation, the different MFIs obtained with either
positive or negative sera and which were indicative of differential
antigen-specific IgG levels, appeared to be fully consistent with the
corresponding IgG titers determined by using a more conventional
ELISA assay (Figure 3), confirming what previously observed by
Robinson et al. [14], who not only demonstrated that chip and
ELISA results correlate but who also highlighted the higher
sensitivity of the array approach.
Two major conclusions can be derived from our protein array
results. The first one is that the serological profiles observed in tic
patients were similar to those observed in sera of patients who
experienced a common acute pharyngitis. In fact our analysis
established that 46 antigens, out of the 102 present on the chip,
reacted against tic and pharyngitis patient sera in a similar
manner, being each of them recognized by comparable percent-
ages of sera from the two groups (Tables 1 and 2). Remarkably, the
profiles of both sera groups were significantly different from those
observed in no tic patients (Table 2 and Figure 2).
The second conclusion coming from the array results is that the
IgG response of tic sera appeared to be overall quantitatively
stronger than that observed in pharyngitis patients. In fact, when
we took into account the frequencies of highly reacting antigens
and sera (MFIs higher than 40,000), they appeared to be
significantly higher in tic patients, compared to both pharyngitis
and no tic patients (Figure 4B and 4C).
Overall, the results discussed so far demonstrated that a large
number of GAS antigens eliciting an immune response in the
course of a common acute pharyngitis were also recognized, and
even more robustly, by tic sera. These data provide the first
evidence that tic patients exhibit serological profiles typical of
individuals who have mounted a broad, specific and strong
immune response against Group A Streptococcus antigens, strength-
ening the relationship between tic disorder and GAS infection, so
far based only on discordant epidemiological reports and few signs
of infection [15].
The established association between tics and GAS infections
raises the question of how and to what extent may the pathogen
contribute to the onset or recurrence of this disorder. This is even
more intriguing considering that the immune response against
Table 2. GAS antigens preferentially reacting against tic and pharyngitis sera.
SPy Annotation Tic Phar
(a) No Tic
SPy0747 hypothetical protein 90 92 51
SPy0031 putative choline binding protein 64 83 29
SPy1032 extracellular hyaluronate lyase 62 74 29
SPy0159 hypothetical protein 59 69 26
SPy0737 putative extracellular matrix binding protein 59 60 17
SPy0793 hypothetical protein 56 65 22
SPy1037 hypothetical protein 54 52 20
SPy0714 putative adhesion protein 54 44 17
SPy2000 surface lipoprotein 52 64 6
SPy1390 putative protease maturation protein 51 77 9
SPy2037 peptidylprolyl isomerase 51 72 9
SPy0252 putative sugar transporter sugar binding lipoprotein 51 69 3
SPy1882 putative acid phosphatase 51 62 9
SPy1983 collagen-like surface protein 51 46 23
M5005_SPy0249
(b) oligopeptidepermease OppA 49 63 20
SPy0287 hypothetical protein 49 60 9
SPy0441 hypothetical protein 43 52 6
SPy2007 putative laminin adhesion 38 27 0
SPy1326 hypothetical protein 38 28 9
SPy2066 putative dipeptidase 33 31 11
SPy0838 hypothetical protein 30 34 4
Numeric values refer to % of positive sera of each class versus each antigen. Recognition percentages from No Tic sera were significantly lower (P,0.05) when
compared to those obtained with either Tic or Pharyngitis sera, as established by using the two-tailed x
2 test.
(a)Pharyngitis.
(b)M5005 SPy number used since the protein, although present, was not annotated in SF370 M1 strain.
doi:10.1371/journal.pone.0006332.t002
Table 3. GAS antigens preferentially reacting against tic sera.
SPy Annotation Tic Phar
(a) No Tic
SPy0453 metal binding protein of ABC
transporter
41 25 9
SPy1939 hypothetical protein 39 13 11
SPy1795 putative ABC transporter 38 22 3
SPy1054 putative collagen-like protein 36 14 3
SPy1306 maltose/maltodextrin-binding protein 34 15 0
Numeric values refer to % of positive sera of each class versus each antigen.
Number of tic, pharyngitis and no tic sera positive against each antigen were
compared using two-tailed x
2 test, resulting in a statistically higher number of
positive tic sera as compared to pharyngitis and no tic sera (P,0.05).
(a)Pharyngitis.
doi:10.1371/journal.pone.0006332.t003
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presence of neuropsychiatric symptoms but in the absence of overt
GAS infection, as testified by the lack of clinical signs of
pharyngitis and by the usual GAS carrier frequency observed in
the tic patient population. Additionally, the fact that no major
differences were observed between tic patients with low or high
ASO titers further suggested that the serological profiles of these
patients were not strictly correlated with the immune response
against SLO, which is the parameter routinely used to confirm an
ongoing or recent GAS-induced pharyngitis.
Still much has to be explained on how GAS infections
contribute to the wide spectrum of post-streptococcal syndrome
of the central nervous system (CNS) [16]. It is assumed that CNS
disease predisposition is dependent on a multiplicity of factors,
among which genetic background [16,17], and that GAS
infections ‘‘per se’’ are not the primary cause of the outcome of
CNS disorders but contribute as cofactors triggering the disorder
outcome or increasing the risk for the disease to occur, especially
in the presence of a particular genetic predisposition.
Induction of non-suppurative sequelae due to ‘‘molecular
mimicry’’ between bacterial antigens and host tissues distinguishes
Group A Streptococcus from related streptococci and most of
other human bacterial pathogens. Protein M is the prototype
antigen causing ‘‘autoimmune sequelae’’, primarily represented by
acute RF and by rheumatic heart disease (RHD). These
pathologies have indeed been linked to mimicry between M
protein and cardiac myosin, due to the immunological response to
GAS infection which would cause induction of specific cross-
reacting antibodies and inflammatory T cells infiltrating and
damaging the myocardium or valve [18,19]. Similar structural and
immunological similarities have been found between M protein
and several other auto antigens such as tropomyosin, vimentin,
keratin and laminin [1]. The glycolytic enolase enzyme has also
been identified as an additional antigen, possibly playing a role in
acute RF development. In fact, antistreptococcal enolase antibod-
ies appeared to cross-react with human enolase and sera from
acute RF patients had higher anti-human and anti-bacterial
enolase titers compared to those found in sera of both pharyngitis
Table 4. Sera reacting against multiple tic-preferentially-recognized antigens.
Number positive antigens
(a) Tic
(b) Pharyngitis
(b) P value
(c) No Tic
(b) P value
(d)
5 23% (14/61) 5% (11/239) ,0.0001 0% (0/35) 0.0057
at least 4 33% (20/61) 6% (15/239) ,0.0001 0% (0/35) 0.0004
at least 3 39% (24/61) 17% (41/239) 0.0003 3% (1/35) 0.0002
(a)number of antigens reported in Table 3 simultaneously recognized by the same serum.
(b)percentages of positive sera (number of positive sera/total sera tested) simultaneously recognizing the number of antigens indicated in the first column.
(c)P values of Tic versus Pharyngitis calculated with two-tailed x
2 test.
(d)P values of Tic versus No Tic calculated with two-tailed x
2 test.
doi:10.1371/journal.pone.0006332.t004
Figure 3. Correlation between sera ELISA titers and MFI. Black circles and triangles represent the ELISA Titers (geometric means, x-axis) and
Mean Fluorescent Intensities (arithmetic means, y-axis) obtained using 8 sera from either no tic or tic patients with each of the antigens Spy0843,
M5005_Spy0249, Spy1306 and Spy1939. Standard errors of the means are reported. Both ELISA titers and MFIs differences between the two sera
classes were statistically significant with P values,0.05 calculated either with T Student (ELISA) or Fisher’s exact test (MFI).
doi:10.1371/journal.pone.0006332.g003
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5 streptococcal antigens and 4 tissue antigens possibly involved in
molecular mimicry, were recently shown to be significantly higher
in acute RF compared to pharyngitis patients [21].
The possibility that post-streptococcal autoimmune events
similar to those mentioned above could play a role in causing or
contributing to neuropsychiatric disorders is still under evaluation.
This hypothesis appeared to be supported by the fact that higher
levels of antibodies directed against brains structures were
observed in children with OCD and PANDAS [22,23] and that
patients with Tourette’s syndrome and tic disorder have increased
titers of antibodies specific for streptococcal M protein [24], which
is known to elicit antibodies cross-reacting with human brains
proteins [25]. Further support to the autoimmune hypothesis
derived from the observations that monoclonal antibodies
obtained from Sydenham’s chorea patients [26] showed specificity
for mammalian lysoganglioside and N-acetyl-b-D- glucosamine
(GlcNAc), the dominant epitope of group A streptococcal
carbohydrate, as well as from data indicating the M1 isoform of
pyruvate kinase [27] and additional neuronal surface glycolytic
enzymes [28] as autoimmune targets in Tourette syndrome and
other CNS diseases.
On the basis of this background, our data demonstrating a
strong immune response against GAS antigens in tic patients even
in the absence of evident infection, suggest that the serological
profile observed in these patients may be relevant in the context of
one of the current hypothesis [23,29] proposing that antibodies
directed against specific streptococcal antigens could be respon-
sible for auto-immune reactions triggering the occurrence of tic
disorders in susceptible individuals. In this scenario, peaks of
autoimmune response against critical GAS antigens may occur
cyclically, due to repeated boosts, as a consequence of either
recurrent infections or re-exposure to the pathogen capable of
surviving within the host, causing periodic release and exacerba-
tion of neuropsychiatric or behavioral symptoms in children.
In conclusion, we believe that our data demonstrated the link
existing between tic disorder and GAS infection and strengthened
the concept that a relationship may exist between tics and
antibody response against Group A Streptococcus antigens. While
it is presently difficult to evaluate whether an immune response
against any of the 51 antigens recognized by tic sera plays indeed a
role, we think that these observations could encourage further
experiments aimed at better defining the role which specific
streptococcal proteins play in the manifestation of children
neuropsychiatric disorders.
Materials and Methods
Selection, expression and purification of GAS surface-
exposed antigens
Computer programs included in the GCG Wisconsin Package
version 11.1, in combination with PSORT program, were used to
analyze the SF370 strain sequence and to select a subset of
predicted surface-exposed and secreted proteins. Proteins included
in the subset were those containing leader peptides, lipoprotein
signature, outer membrane anchoring motives, host cell binding
domains such as RGD and homologies to known surface proteins
or to known virulence factors. As a result of this activity, 96 genes
were selected from SF370, cloned and expressed in E. coli both as
a C-terminal His-tag fusion protein or as a double fusion protein
with an N-terminal GST peptide and a C-terminal His-tag [30].
Following IMAC or Glutathione-sepharose affinity-chromatogra-
phy, the antigens were successfully purified from the bacterial
soluble fraction, dialyzed against PBS buffer and used to assemble
Figure 4. Relative reactivity of the three sera classes. A,
Percentages of tested GAS antigens recognized by at least 30% of sera
for each patient group. B, Percentages of antigens recognized by at
least 30% of the sera of each class with FI.40,000. C, Percentages of
sera for each class reacting with at least 30% of the antigens and with
FI.40,000. Numbers above histograms bars indicate P values calculated
with the two-tailed x
2 test.
doi:10.1371/journal.pone.0006332.g004
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cloned from strains with different M types and the corresponding
proteins were purified and spotted on the chip. The proteins were:
M1 from SF370, M2 from 2726 strain, M3 from MGAS315, M9
from 2720 strain, M12 from 2728 strains and M23 from
DSM2071. All antigens are listed in Supplementary Table S1.
Protein micro array technology
The GAS protein array was generated by spotting affinity-
purified recombinant protein (0.5 mg/ml) in 4 replicates on
nitrocellulose-coated slides (FAST slides, Schleicher and Schuell)
with the Chipwriter Pro spotter (Biorad), resulting in spots of
approximately 150 mm in diameter. As experimental positive
controls to assess the sensitivity and reproducibility of the array set
up and for data normalization, a curve of human IgG(s) (solutions
from 0.008 to 1 mg/ml) was spotted on the arrays in 8 replicates
and detected with Cy3 conjugated a-human IgG secondary
antibody. Similarly, a curve of human IgM(s) was also spotted on
the arrays, which were undetectable under tested conditions. PBS
buffer was spotted in at least twice the number of the protein spots,
and used to assess the possible non-specific signal due to cross
contamination. For experiments with human sera, slides were
saturated with blocking solution 3% Top Block (Fluka-BioChem-
iKa) 20,1% Tween 20 in PBS (TPBS), and later incubated with
sera (1:1000 dilutions in TPBS) for 1 h at room temperature. After
three washes for 5 min in 0.1% TPBS, slides were incubated with
Cy3 conjugated anti-human IgG (Southern Biotech) for 1 h at
room temperature in the dark. Afterwards arrays were washed
twice with TPBS, once with PBS and finally with milliQ sterile
water (30 seconds) and were then dried at 37uC for 10–20 minutes
in the dark and scanned. Each serum was tested at least twice.
Spotting was validated by confirming the presence of all
immobilized proteins using mouse anti-GST and anti-His6 tags
monoclonal antibodies, followed by detection with a Cy3 labeled
a-mouse IgG secondary antibody. Fluorescence signals were
detected by using a ScanArray 5000 Unit (Packard, Billerica,
MA, USA) and the 16-bit images images were generated with
ScanArrayTM software at 10 mm per pixel resolution and
processed using ImaGene 6.0 software (Biodiscovery Inc, CA,
USA). Elaboration and analysis of image raw fluorescence
Intensity (FI) data was performed using an in house-developed
software. For each sample, the mean fluorescence intensity (MFI)
of replicated spots was determined, after subtraction of the
background value surrounding each spot, and subsequently
normalized on the basis of the human IgG curve to allow
comparison of data from different experiments. The MFIs values
of IgG, spotted at different concentrations, were best fitted by a
curve belonging to sigmoid family using a maximum likelihood
estimator [31]. The normalization method has been set up by
defining a reference IgG curve that covers the entire 16 bits pixel
range, adjusting the experimental IgG curve and normalizing
protein MFIs values accordingly. With the following formula we
get the normalized MFI value from the experimental MFI value
(Reguzzi V., personal communication):
Normalized Value~LLidz
HLid{LLid ðÞ
1z
HL{Value ðÞ
Value{LL ðÞ
 s
sid:e
(mid{m)
sid
where HLid, LLid, sid and mid are the parameters for the
reference sigmoid and HL, LL, sid and mid are the parameters for
experimental IgG curve.
In order to profile the specificity of the antigenic responses of
each serum and to define the antigen recognition pattern of the
three classes of sera, the normalized MFI values were subjected to
unsupervised bi-dimensional hierarchical clustering using TIGR
Multiexperiment Viewer (MeV) software (http://www.tigr.org/
software/tm4/mev.html).
Human sera
‘‘Pharyngitis’’ sera were collected from 249 male and female
patients aged 4–14 with clinical symptoms of pharyngitis. A throat
swab was performed at diagnosis which confirmed pharyngitis
being GAS-associated and allowed the isolation of the GAS
infective strain, which was then serotyped according to the
sequence of the specific M protein antigen. Among the isolated
strains, all of the epidemiologically most important M types were
represented.
‘‘Tic’’ sera were collected from patients affected by tic disorders
during their first observation at outpatient division of The
Department of Child and Adolescent Neuropsychiatry of the
University of Rome La Sapienza between September 2004 and
July 2005. Inclusion criteria comprised to be affected by tic
disorders; exclusion criteria comprised mental retardation, perva-
sive developmental disorders, tics secondary to neurodegenerative
diseases or structural brain lesions of vascular, traumatic or
inflammatory origin; prior assumption of drugs or toxins
potentially causing secondary tics; children with proved immuno-
logic deficits; non ambulant subjects; institutionalized children. In
total, 61 consecutive patients (6 females) affected by tic disorder
aged 4–14 years (mean: 9,6; median: 9,2) were studied. All patients
were coming from Rome and its province and were attending
normal schools. Seventeen patients were recruited during fall, 20
during winter, 18 during spring and 8 during summer. In the large
majority of cases the observation occurred during a period of
symptom exacerbation in subjects having had tics for months or
years; only 3 patients were examined at the onset of tic symptoms.
In these patients the severity of tics, as measured by the Yale
Global Tic Severity Scale, ranged between 15 and 35 (without
impairment score). No patient showed clinical signs of pharingo-
tonsillitis; 9 patients (14.75%) had a pharyngeal swab positive for
GAS. All isolates were typed according to the sequence of the M
protein antigen (emm typing). The types identified covered several
M types with no prevalence of any specific type. Regarding anti-
streptolysin O (ASO) titers, 14 patients showed normal values
(,200 International Units, I.U.), 16 intermediate values (200–
400 I.U.), 19 elevated values (400–1,000 I.U.) and 12 very
elevated values (.1,000 I.U.) No direct correlation by swab
positivity for GAS and ASO titer was observed but the mean value
for GAS positive patients was in the range that we classified as
elevated (about 650 IU). In all, 50.81% of the patients had ASO
titers elevated or very elevated. The season of recruitment of
patients was not correlated with ASO titer values or with swab
positivity for GAS.
‘‘No tic’’ sera were collected from 35 outpatients (4 females)
aged 4–14 years (mean: 8,9; median: 9,1) affected by benign
epilepsies attending to The Department of Child and Adolescent
Neuropsychiatry of the University of Rome La Sapienza. All
patients were coming from Rome or its province and were
attending normal schools. The controls were matched to the tic
patients for sex, age and time (season of the year) of observation.
No patient had tic symptoms or pharingo-tonsillitis. Regarding
ASO titer, 16 patients showed normal values (,200 I.U.), 15
intermediate values (200–400 I.U.) and then 4 elevated values
(400–1000 I.U.). In all 11.42% of the patients had elevated, and
none had very elevated ASO titers.
Human sera were not obtained specifically for this study but
were residuals of routine samples collected for diagnosis purposes,
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Policlinico Umberto Iu, Universita ` La Sapienza, and the
Institutional Review Board of the Methodist Hospital Research
Institute authorized the use of residual materials for research
purposes. No formal consent was required to perform protein chip
experiments since sera and data were used and analyzed
anonymously.
Statistical analysis
Statistical differences among sera groups, ELISA titers and
MFIs were analyzed using the two-tailed x
2, the T student or the
Fisher’s exact tests. Differences were considered statistically
significant when P values below 0.05 were obtained.
Supporting Information
Figure S1 GAS antigens preferentially reacting against tic sera.
Box and Whiskers plot analysis of Mean Fluorescence Intensity
(MFI) values of all Tic, No Tic and Pharyngitis tested sera against
the 5 antigens reported in Table III. Medians and extreme values
(black dots) are shown.
Found at: doi:10.1371/journal.pone.0006332.s001 (0.40 MB TIF)
Table S1 In silico selected GAS antigens.
Found at: doi:10.1371/journal.pone.0006332.s002 (0.09 MB
DOC)
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